09:29 AM EDT, 09/18/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Thursday it has signed a reimbursement deal with the Italian Medicines Agency for eligible patients to access Casgevy, a gene-edited therapy to treat transfusion-dependent beta thalassemia and severe sickle cell disease.
Financial terms were not disclosed.